Zacks Investment Research upgraded shares of American Renal Associates Holdings, Inc (NYSE:ARA) from a hold rating to a buy rating in a report published on Thursday. Zacks Investment Research currently has $13.00 price objective on the stock.

According to Zacks, “American Renal Associates Holdings, Inc. is a provider of dialysis services primarily in the United States. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure. American Renal Associates Holdings, Inc. is based in Beverly, Massachusetts. “

Separately, SunTrust Banks, Inc. set a $18.00 price target on shares of American Renal Associates Holdings and gave the company a buy rating in a report on Sunday, October 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. American Renal Associates Holdings presently has an average rating of Hold and an average target price of $18.00.

Shares of American Renal Associates Holdings (NYSE ARA) traded up $0.41 during trading on Thursday, hitting $13.03. 334,046 shares of the company were exchanged, compared to its average volume of 274,027. The company has a current ratio of 1.16, a quick ratio of 1.14 and a debt-to-equity ratio of 3.57. The firm has a market capitalization of $409.94, a price-to-earnings ratio of 19.45, a P/E/G ratio of 1.13 and a beta of 3.64. American Renal Associates Holdings has a fifty-two week low of $9.91 and a fifty-two week high of $24.94.

American Renal Associates Holdings (NYSE:ARA) last issued its quarterly earnings results on Tuesday, November 14th. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.03. The business had revenue of $187.71 million during the quarter, compared to analyst estimates of $194.60 million. American Renal Associates Holdings had a negative net margin of 2.15% and a positive return on equity of 15.80%. American Renal Associates Holdings’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.28 earnings per share. equities analysts anticipate that American Renal Associates Holdings will post 0.55 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/american-renal-associates-holdings-inc-ara-lifted-to-buy-at-zacks-investment-research/1714193.html.

Several institutional investors have recently modified their holdings of the stock. Atria Investments LLC increased its holdings in shares of American Renal Associates Holdings by 2.2% in the second quarter. Atria Investments LLC now owns 10,943 shares of the company’s stock valued at $203,000 after purchasing an additional 233 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in American Renal Associates Holdings by 0.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 39,132 shares of the company’s stock worth $726,000 after acquiring an additional 285 shares during the period. Rhumbline Advisers grew its holdings in American Renal Associates Holdings by 2.7% during the 2nd quarter. Rhumbline Advisers now owns 13,383 shares of the company’s stock worth $248,000 after acquiring an additional 354 shares during the period. Alliancebernstein L.P. grew its holdings in American Renal Associates Holdings by 3.0% during the 2nd quarter. Alliancebernstein L.P. now owns 13,900 shares of the company’s stock worth $258,000 after acquiring an additional 400 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in American Renal Associates Holdings by 19.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 8,778 shares of the company’s stock worth $162,000 after acquiring an additional 1,443 shares during the period. 89.98% of the stock is owned by institutional investors and hedge funds.

About American Renal Associates Holdings

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Get a free copy of the Zacks research report on American Renal Associates Holdings (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.